Skip to main content

CWLXF · C21 Investments Inc.

Track CWLXF — free
Market Cap
$31.41M
Shares
118.68M

No Price Data

No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Limited Momentum Limited Sentiment Bullish Fundamentals Excellent Quant / Vol Limited
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Limited
Not enough data for a confident read.
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Fundamentals
Excellent
Revenue growth +8%
Y/Y
Gross margin 42%
expanding
EPS growth 0%
Y/Y
Quant / Vol
risk profile
Limited
Not enough data for a confident read.

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CWLXF
C21 Investments Inc.
this stock
$31.41M +8.3% 0.1%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
$66.37B 0.0%
TAK
Takeda Pharmaceutical Co Ltd
$58.92B +18.3% 0.1%
GALDY
Galderma Group AG/ADR
$45.51B -5.8% 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$42.37B +16.5% +4.3% 59.6 3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1
% held
0.1%
Net QoQ
+75.0K sh
Top holder
GOFEN & GLOSSBERG LLC /IL/
Held Float
View
Financials
Financials
Revenue (FY)
$32.6M
Net income (FY)
$-3.2M
EPS diluted
$-0.03
View
Buybacks
Authorized
shares 6.0M
Remaining
shares 5.9M
Spent Remaining
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 21, 2026
This year
9
View
Key facts CIK 831609 CUSIP 12675Q101 Visit website Investor relations